Clostridium difficile infection and fecal microbiota transplant

Alyssa Liubakka, Byron P. Vaughn

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent CDI. This review covers the current epidemiology of CDI (including toxigenic and nontoxigenic strains, risk factors for infection, and recurrent infection), methods of diagnosis, existing first-line therapies in CDI, the role of fecal microbiota transplant for multiple recurrent CDIs, and the potential use of fecal microbial transplant for patients with severe or refractory infection.

Original languageEnglish (US)
Pages (from-to)324-337
Number of pages14
JournalAACN advanced critical care
Issue number3
StatePublished - Nov 28 2016

Bibliographical note

Publisher Copyright:
© 2016 AACN.


  • Clostridium Difficile Infection
  • Fecal Microbiota Transplant
  • Fecal Transplant
  • Recurrent C Difficile Infection


Dive into the research topics of 'Clostridium difficile infection and fecal microbiota transplant'. Together they form a unique fingerprint.

Cite this